Patents by Inventor John Gary Montana
John Gary Montana has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10822342Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: February 1, 2019Date of Patent: November 3, 2020Assignee: Janssen Pharmaceutica NVInventors: George Hynd, Patrizia Tisselli, Calum MacLeod, Samuel Edward Mann, Terry Aaron Panchal, John Gary Montana, Stephen Colin Price
-
Patent number: 10626089Abstract: Crystals of [8-chloro-3-(4-chlorobenzyl)-4-difluoromethoxy-2-ethylquinolin-5-yloxy]acetic acid L-lysine salt, i.e., a crystal A which has peaks at diffraction angles 2?=6.0°, 10.0°, 10.7°, 12.1°, 18.4°, 19.2° and 20.1° in powder X-ray diffraction spectra and a crystal B which has peaks at diffraction angles 2?=6.0°, 11.7°, 12.4°, 15.2°, 16.4°, 20.3° and 22.6° in powder X-ray diffraction spectra. These crystals are chemically stable and have excellent thermal stability and physical properties, and are therefore suitable as medicinal substances.Type: GrantFiled: July 25, 2019Date of Patent: April 21, 2020Assignee: GBOO1, Inc.Inventors: Donald John Daley, John Gary Montana, George Hynd, Mitsuru Teramoto, Takahiro Ito
-
Publication number: 20200017447Abstract: Crystals of [8-chloro-3-(4-chlorobenzyl)-4-difluoromethoxy-2-ethylquinolin-5-yloxy]acetic acid L-lysine salt, i.e., a crystal A which has peaks at diffraction angles 2?=6.0°, 10.0°, 10.7°, 12.1°, 18.4°, 19.2° and 20.1° in powder X-ray diffraction spectra and a crystal B which has peaks at diffraction angles 2?=6.0°, 11.7°, 12.4°, 15.2°, 16.4°, 20.3° and 22.6° in powder X-ray diffraction spectra. These crystals are chemically stable and have excellent thermal stability and physical properties, and are therefore suitable as medicinal substances.Type: ApplicationFiled: July 25, 2019Publication date: January 16, 2020Inventors: Donald John Daley, John Gary Montana, George Hynd, Mitsuru Teramoto, Takahiro Ito
-
Publication number: 20190276405Abstract: Crystals of [8-chloro-3-(4-chlorobenzyl)-4-difluoromethoxy-2-ethylquinolin-5-yloxy]acetic acid L-lysine salt, i.e., a crystal A which has peaks at diffraction angles 2?=6.0°, 10.0°, 10.7°, 12.1°, 18.4°, 19.2° and 20.1° in powder X-ray diffraction spectra and a crystal B which has peaks at diffraction angles 2?=6.0°, 11.7°, 12.4°, 15.2°, 16.4°, 20.3° and 22.6° in powder X-ray diffraction spectra. These crystals are chemically stable and have excellent thermal stability and physical properties, and are therefore suitable as medicinal substances.Type: ApplicationFiled: May 15, 2017Publication date: September 12, 2019Inventors: Donald John Daley, John Gary Montana, George Hynd, Mitsuru Teramoto, Takahiro Ito, Taro Tameyama
-
Patent number: 10323045Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: October 22, 2015Date of Patent: June 18, 2019Assignee: Janssen Pharmaceutica NVInventors: George Hynd, Patrizia Tisselli, Calum Macleod, Samuel Edward Mann, John Gary Montana, Stephen Colin Price
-
Publication number: 20190169198Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: ApplicationFiled: February 1, 2019Publication date: June 6, 2019Inventors: George HYND, Patrizia Tisselli, Calum Macleod, Samuel Edward Mann, Terry Aaron Panchal, John Gary Montana, Stephen Colin Price
-
Patent number: 10221180Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: October 22, 2015Date of Patent: March 5, 2019Assignee: Janssen Pharmaceutica NVInventors: George Hynd, Patrizia Tisselli, Calum Macleod, Samuel Edward Mann, Terry Aaron Panchal, John Gary Montana, Stephen Colin Price
-
Publication number: 20180298032Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: ApplicationFiled: October 22, 2015Publication date: October 18, 2018Inventors: George HYND, Patrizia TISSELLI, Calum MACLEOD, Samuel Edward MANN, John Gary MONTANA, Stephen Colin PRICE
-
Patent number: 10005773Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: September 25, 2014Date of Patent: June 26, 2018Assignee: Janssen Pharmaceutica NVInventors: George Hynd, Patrizia Tisselli, David Edward Clark, Janusz Jozef Kulagowski, Calum MacLeod, Samuel Edward Mann, Terry Aaron Panchal, Stephen Colin Price, John Gary Montana
-
Patent number: 10005776Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: October 22, 2015Date of Patent: June 26, 2018Assignee: Janssen Pharmaceutica NVInventors: George Hynd, Patrizia Tisselli, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann, Stephen Colin Price, John Gary Montana
-
Patent number: 9981963Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: September 25, 2014Date of Patent: May 29, 2018Assignee: Janssen Pharmaceutica NVInventors: George Hynd, Patrizia Tisselli, David Edward Clark, Janusz Jozef Kulagowski, Calum MacLeod, Samuel Edward Mann, Fabien Jean Ghislain Roussel, Stephen Colin Price, John Gary Montana
-
Patent number: 9981962Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: October 22, 2015Date of Patent: May 29, 2018Assignee: Janssen Pharmaceutica NVInventors: George Hynd, Patrizia Tisselli, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann, John Gary Montana, Stephen Colin Price, Fabien Jean Ghislain Roussel
-
Publication number: 20170334900Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: ApplicationFiled: October 22, 2015Publication date: November 23, 2017Inventors: George HYND, Patrizia TISSELLI, Janusz Josef KULAGOWSKI, Calum MACLEOD, Samuel Edward MANN, John Gary MONTANA, Stephen Colin PRICE, Fabien Jean Ghislain ROUSSEL
-
Patent number: 9643964Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: April 24, 2014Date of Patent: May 9, 2017Assignee: Janssen Pharmaceutica NVInventors: George Hynd, Stephen Price, Janusz Kulagowski, Calum MacLeod, Samuel Edward Mann, Terry Aaron Panchal, Patrizia Tisselli, John Gary Montana
-
Publication number: 20160257679Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: ApplicationFiled: September 25, 2014Publication date: September 8, 2016Inventors: George HYND, Patrizia TISSELLI, David Edward CLARK, Janusz Jozef KULAGOWSKI, Calum MACLEOD, Samuel Edward MANN, Terry Aaron PANCHAL, Stephen Colin PRICE, John Gary MONTANA
-
Publication number: 20160229851Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: ApplicationFiled: September 25, 2014Publication date: August 11, 2016Inventors: George HYND, Patrizia TISSELLI, David Edward CLARK, Janusz Jozef KULAGOWSKI, Calum MACLEOD, Samuel Edward MANN, Fabien Jean Ghislain ROUSSEL, Stephen Colin PRICE, John Gary MONTANA
-
Publication number: 20160075699Abstract: The present invention relates to compounds of formula (I) which are inhibitors of NF-KB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: ApplicationFiled: April 24, 2014Publication date: March 17, 2016Applicant: Janssen Pharmaceutica N.V.Inventors: George HYND, Stephen PRICE, Janusz KULAGOWSKI, Calum MACLEOD, Samuel Edward MANN, Terry Aaron PANCHAL, Patrizia TISSELLI, John Gary MONTANA
-
Patent number: 8394830Abstract: Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, for example, asthma and COPD wherein: R1 is halogen or cyano; R2 is hydrogen or methyl; R3 and R4 are independently —OR6, C1-C6alkyl or C3-C6cycloalkyl, the latter two groups being optionally substituted by one or more halogen atoms; R5 is hydrogen or halogen; R6 is C1C6alkyl or C3-C6cycloalkyl, either of which being optionally substituted by one or more halogen atoms; X is —CH2—, —S—, or —O—; one of Y and Y1 is hydrogen and the other is OR6, —C(?O)R7, NR8SO2R6 or a heterocyclic group selected from those referred to in the specification; and R6, R7 and R8 are as defined in the specification.Type: GrantFiled: March 30, 2012Date of Patent: March 12, 2013Assignee: Pulmagen Therapeutics (Asthma) LimitedInventors: John Gary Montana, Harry Finch, George Hynd, Michael Colin Cramp, Rosa Arienzo, Neville McLean
-
Patent number: 8394836Abstract: Compound of formula (I) are ligands of the CRTH2 receptor, useful inter alia for treatment of inflammatory conditions.Type: GrantFiled: December 12, 2008Date of Patent: March 12, 2013Assignee: Pulmagen Therapeutics (Asthma) LimitedInventors: George Hynd, John Gary Montana, Harry Finch, Rosa Arienzo, Barbara Avitabile-Woo, Mathias Domostoj
-
Publication number: 20120184579Abstract: Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, for example, asthma and COPD wherein: R1 is halogen or cyano; R2 is hydrogen or methyl; R3 and R4 are independently —OR6, C1-C6alkyl or C3-C6cycloalkyl, the latter two groups being optionally substituted by one or more halogen atoms; R5 is hydrogen or halogen; R6 is C1C6alkyl or C3-C6cycloalkyl, either of which being optionally substituted by one or more halogen atoms; X is —CH2—, —S—, or —O—; one of Y and Y1 is hydrogen and the other is OR6, —C(?O)R7, NR8SO2R6 or a heterocyclic group selected from those referred to in the specification; and R6, R7 and R8 are as defined in the specification.Type: ApplicationFiled: March 30, 2012Publication date: July 19, 2012Inventors: John Gary Montana, Harry Finch, George Hynd, Michael Colin Cramp, Rosa Arienzo, Neville McLean